A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults With Idiopathic Pulmonary Fibrosis (SURPASS-IPF)
Principal Investigator
Dr Peter Saunders
Contact us
Email: samantha.chilcott@ndm.ox.ac.uk
IRAS number
1014222